Content area
Abstract
The skeleton is the most common metastatic site in patients with advanced cancer. Pain is a major healthcare problem in patients with bone metastases. Bone-seeking radionuclides that selectively accumulate in the bone are used to treat cancer-induced bone pain and to prolong survival in selected groups of cancer patients. The goals of these guidelines are to assist nuclear medicine practitioners in: (a) evaluating patients who might be candidates for radionuclide treatment of bone metastases using beta-emitting radionuclides such as strontium-89 (89Sr), samarium-153 (153Sm) lexidronam (153Sm-EDTMP), and phosphorus-32 (32P) sodium phosphate; (b) performing the treatments; and ©) understanding and evaluating the treatment outcome and side effects.
Details
; Poeppel, Thorsten D 2 ; Bodei, Lisa 3 ; Aktolun, Cumali 4 ; Ezziddin, Samer 5 ; Giammarile, Francesco 6 ; Delgado-Bolton, Roberto C 7 ; Gabriel, Michael 8 1 Nuclear Medicine and Endocrine Oncology Department, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland
2 Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany
3 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
4 Tirocenter Nuclear Medicine Center, Istanbul, Turkey
5 Nuclear Medicine, University Hospital USK, Saarland University, Hamburg, Germany
6 Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency (IAEA), Vienna, Austria
7 Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain
8 Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Linz, Austria; University Clinic of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria